Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

Area of Science:

• Oncology
• Molecular Biology
• Immunohistochemistry

Background:

• CEACAM6 (NCA-90) and CEACAM5 (CEA) are expressed in various carcinomas, including breast, pancreatic, colonic, and lung.
• Antibodies targeting CEACAM6 and CEACAM5 can impact tumor cell growth.
• Investigating CEACAM6 and CEACAM5 expression relative to histological phenotype is crucial for understanding their roles in cancer.

Purpose of the Study:

• To compare the expression levels of CEACAM6 and CEACAM5 across different cancer types and histological subtypes.
• To analyze CEACAM6 and CEACAM5 expression in patient-matched normal, primary tumor, and metastatic tissues.
• To correlate antigen expression with histological phenotype in breast, pancreatic, lung, ovarian, and prostate cancers.

Main Methods:

• Immunohistochemistry (IHC) was employed using specific antibodies (MN-15, MN-3 for CEACAM6; MN-14 for CEACAM5).
• Tissue microarrays were utilized for analyzing antigen expression in various cancer specimens.
• Expression levels were quantified using an average score, with avidin-biotin-diaminobenzide staining.

Main Results:

• CEACAM6 expression was generally higher than CEACAM5 across all tumor types studied.
• CEACAM6 levels varied significantly with histotype; for example, higher in papillary breast tumors and mucinous ovarian adenocarcinomas.
• Liver metastases of colonic carcinoma showed higher CEACAM6 than primary tumors, while lymph node metastases showed similar levels to primary tumors.

Conclusions:

• CEACAM6 is upregulated in numerous solid tumors, but its expression is histotype-dependent.
• CEACAM6 plays a role in tumor cell migration, invasion, adhesion, and metastasis formation.
• CEACAM6 represents a potential therapeutic target for antibody-based cancer treatments.